CJC-1295 for Recovery: Off-Label Evidence Summary

What Is CJC-1295 and Why Is It Used Off-Label?

CJC-1295 is a synthetic 30-amino-acid peptide analog of endogenous GHRH, modified at four positions (Ala2, Asn8, Ala15, Leu27) to resist dipeptidyl peptidase IV (DPP-IV) cleavage [1]. Two forms circulate in clinical and compounding contexts: the Drug Affinity Complex (DAC) version, which covalently binds albumin to extend its half-life to roughly 5.8 to 8 days, and the non-DAC version (often called modified GRF 1-29 or mod-GRF), with a half-life near 30 minutes [2].

Neither form has received FDA approval. The FDA's approved GHRH analogs are limited to tesamorelin (Egrifta), indicated only for HIV-associated lipodystrophy [3]. CJC-1295 occupies a regulatory gray zone: it is available through 503A and 503B compounding pharmacies, and the FDA has issued warning letters to firms marketing it for anti-aging or performance claims [4]. Recovery-focused use (post-exercise soreness reduction, tendon or ligament healing acceleration, post-surgical tissue repair) is entirely off-label. Clinicians who prescribe it draw on the well-characterized anabolic and reparative effects of the GH-IGF-1 axis rather than on direct evidence for CJC-1295 itself [5].

Pharmacology: How CJC-1295 Raises GH and IGF-1

The peptide binds the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, triggering cyclic AMP signaling and dose-dependent GH secretion [6]. In the key Phase I/II ascending-dose study by Teichman et al. (2006, N=56 healthy adults), a single 30 mcg/kg subcutaneous dose of CJC-1295 DAC increased mean GH levels 2- to 10-fold above baseline, with elevation persisting for at least 6 days [2]. Mean IGF-1 rose 1.5- to 3-fold and remained above baseline at day 11 [2].

This prolonged pharmacodynamic profile distinguishes CJC-1295 DAC from native GHRH, which produces a GH pulse lasting under 2 hours [7]. The non-DAC form (mod-GRF 1-29) generates a shorter but sharper GH pulse, and practitioners often pair it with a ghrelin mimetic such as ipamorelin to amplify pulsatile release [8]. GH in turn stimulates hepatic and local IGF-1 production, the downstream effector most directly tied to collagen synthesis, satellite cell activation, and protein accretion in skeletal muscle [9].

The GH-IGF-1 Axis in Recovery: What the Evidence Actually Shows

GH and IGF-1 are established regulators of tissue repair. That statement rests on decades of mechanistic and clinical data, not on CJC-1295 trials per se. Recombinant human GH (rhGH) accelerated nitrogen balance recovery in burn patients (Herndon et al., Annals of Surgery, 1990) [10] and improved wound healing velocity in a randomized trial of elderly hip-fracture patients (N=20, Yeo et al., 2003) [11]. IGF-1 infusion increased muscle protein synthesis rates by 47% in healthy volunteers (Fryburg et al., 1995), confirming the anabolic signal that recovery-focused CJC-1295 prescribers hope to replicate [12].

For connective tissue, systemic GH administration for 14 days increased collagen type I and III mRNA expression in human tendon biopsies (Doessing et al., 2010, N=20) [13]. A 2005 systematic review in the Journal of Bone and Joint Surgery found moderate evidence that GH supplementation improved fracture healing rates in animal models, though human fracture data remained sparse [14].

The inferential chain is: CJC-1295 raises endogenous GH and IGF-1, and elevated GH/IGF-1 promotes tissue repair. That logic is pharmacologically plausible. It is not the same as proven. No published randomized controlled trial has administered CJC-1295 to injured or post-surgical subjects and measured a recovery endpoint such as return-to-play time, wound tensile strength, or muscle damage biomarker clearance.

Clinical Trial Data Specific to CJC-1295

Published human data on CJC-1295 are narrow. The Teichman et al. Phase I/II dose-escalation study (2006) established PK/PD parameters and short-term safety in 56 healthy men and women [2]. A follow-on multiple-dose study confirmed sustained GH and IGF-1 elevation with weekly injections over 12 weeks, but the primary endpoint was hormonal, not functional [15].

An unpublished Phase II trial of CJC-1295 DAC for GH-deficient adults was terminated early after one subject death. The cause was not fully disclosed publicly, but the trial's discontinuation limited further clinical development of the DAC formulation [16]. This event is not a contraindication to the non-DAC mod-GRF peptide (a distinct pharmacokinetic profile with shorter exposure), but it underscores that safety data remain incomplete.

No registered trials on ClinicalTrials.gov currently list CJC-1295 with recovery, rehabilitation, or tissue-healing endpoints [17]. The Endocrine Society's 2019 clinical practice guideline on GH use in adults does not mention CJC-1295 or any GHRH analog for recovery indications; it restricts GH replacement to patients with confirmed GH deficiency diagnosed by validated stimulation testing [18].

How Practitioners Use CJC-1295 Off-Label for Recovery

Despite the evidence gap, compounding pharmacy data and clinician surveys indicate growing off-label use. Typical protocols reported in anti-aging medicine literature include mod-GRF 1-29 at 100 mcg subcutaneously, often combined with ipamorelin 100 to 200 mcg, administered 1 to 3 times daily, 5 days on and 2 days off [8]. Timing is usually pre-sleep to coincide with endogenous nocturnal GH pulsatility [19].

Clinicians targeting post-exercise recovery often run 8- to 12-week cycles, monitoring IGF-1 serum levels every 4 weeks. Target IGF-1 ranges vary by practice, but most aim for the upper quartile of the age-adjusted reference range (roughly 200 to 300 ng/mL for adults aged 30 to 50) without exceeding it [18]. CJC-1295 DAC, dosed at 1 to 2 mg subcutaneously once weekly, produces a more sustained IGF-1 elevation and is sometimes preferred for patients who want fewer injections [2].

These protocols are experience-based. No dose-finding study has optimized CJC-1295 for any recovery metric. The Anti-Aging and Regenerative Medicine fellowship community has published consensus opinions but not randomized data [20].

Comparing CJC-1295 to FDA-Approved Alternatives

Tesamorelin (Egrifta) is the only FDA-approved GHRH analog. Its labeled indication is reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [3]. Tesamorelin raises GH comparably to CJC-1295 (mean 24-hour GH AUC increased approximately 2-fold), and its Phase III trials (N=816) documented concurrent IGF-1 elevation [21]. However, its approval pathway focused on visceral adiposity, not on musculoskeletal recovery.

Recombinant GH (somatropin) itself is FDA-approved for adult GH deficiency, Turner syndrome, chronic renal insufficiency, and several other conditions [22]. Off-label rhGH for sports recovery is banned by WADA and carries supraphysiologic exposure risks including carpal tunnel syndrome, edema, and insulin resistance [23]. CJC-1295's theoretical advantage is a more physiologic pulsatile GH release pattern, since it stimulates the pituitary rather than replacing GH directly. Whether this translates into a better safety or efficacy profile remains unproven.

Sermorelin, another GHRH analog (GRF 1-29 without amino acid substitutions), was previously FDA-approved for diagnostic use and pediatric GH deficiency but was withdrawn from the market for commercial reasons, not safety [24]. It shares CJC-1295's mechanism but has a shorter half-life (10 to 20 minutes) and weaker receptor binding affinity.

Safety Profile and Risks

Short-term adverse events in the Teichman et al. trial included injection-site erythema (10 to 25% of subjects), transient flushing, diarrhea, and headache [2]. Dose-proportional injection-site induration was the most common local reaction with the DAC formulation.

The single death in the unpublished CJC-1295 DAC trial introduces uncertainty that cannot be dismissed. Without a published autopsy or causality analysis, the event remains unexplained [16]. Practitioners using the non-DAC peptide (mod-GRF 1-29) argue that its brief half-life limits cumulative GH exposure and reduces risk, but this is a theoretical distinction without comparative safety data.

Chronic GH elevation, regardless of the stimulus, carries metabolic consequences. The Endocrine Society warns that supraphysiologic IGF-1 levels are associated with increased colorectal and prostate cancer risk in epidemiologic studies, though a causal relationship is not established [18]. Patients using CJC-1295 long-term (beyond 12 weeks) should have IGF-1, fasting glucose, and hemoglobin A1c monitored at minimum [18]. Joint stiffness, water retention, and new-onset carpal tunnel symptoms should prompt dose reduction or discontinuation.

CJC-1295 is not classified as a controlled substance under federal law, but it falls outside FDA-approved drug categories. WADA prohibits all GH-releasing peptides in competition and out-of-competition testing [23]. Athletes subject to anti-doping rules cannot use it.

Evidence Grade Summary

By GRADE framework criteria, the evidence for CJC-1295 as a recovery agent rates as very low. The body of evidence consists of indirect pharmacodynamic studies (healthy-volunteer PK/PD data showing GH and IGF-1 elevation), extrapolation from rhGH trials in different populations (burns, hip fractures, GH-deficient adults), and absence of any directly relevant RCT [25]. Imprecision is high because no study has measured a recovery-specific outcome after CJC-1295 administration. Risk of bias is unassessable for the unpublished terminated trial.

The Endocrine Society, AACE, and FDA have not issued statements endorsing or specifically prohibiting CJC-1295 for recovery [18]. It remains a pharmacologically rational but clinically unvalidated intervention.

Who Might Be a Candidate (and Who Is Not)

Practitioners offering CJC-1295 for recovery typically screen for confirmed low or low-normal IGF-1 (below the 25th percentile for age), subjective delayed recovery from training or injury, and absence of contraindications including active malignancy, uncontrolled diabetes, or proliferative retinopathy [18]. Patients with a history of pituitary adenoma or elevated baseline IGF-1 should not receive GHRH analogs [18].

Women who are pregnant or breastfeeding lack any safety data for CJC-1295. Adolescents with open growth plates face theoretical risk of accelerated epiphyseal closure, though this has not been studied with CJC-1295 specifically [22].

Evidence does not establish that GH or GHRH analogs improve athletic performance or recovery in healthy adults.